Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1276 to 1290 of 1809 results for nice guidelines

  1. Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)

    Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.

  2. Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)

    NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .

  3. Hernia

    Discontinued [GID-CGWAVE0771]

  4. Upadacitinib for treating moderate rheumatoid arthritis (TA744)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.

  5. What overall osmolality (or concentration of calcium and glucose/dextrose) in parenteral nutrition can determine whether to administer centrally or peripherally?

    the solution is compromised) that are commonly used as evidence in NICE guidelines, so the committee made the recommendation based on a...

  6. Reducing the mortality and morbidity for healthcare associated infections

    Discontinued [GID-NG10059]

  7. Technology appraisal data

    Explore data about our technology appraisal guidance

  8. Transperineal biopsy for diagnosing prostate cancer (DG54)

    Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer

  9. NICE health technology evaluations: the manual (PMG36)

    This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website.

  10. Sebelipase alfa for treating Wolman disease (HST30)

    Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.

  11. Galaxy UNYCO for temporary stabilisation of lower limb fractures (MIB166)

    NICE has developed a medtech innovation briefing (MIB) on Galaxy UNYCO for temporary stabilisation of lower limb fractures .

  12. Workplace health - older employees

    Discontinued [GID-PHG59]

  13. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)

    Evidence-based recommendations on lusutrombopag (Mulpleo) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.

  14. Terms and conditions

    Terms and conditions for the National Institute for Health and Care Excellence

  15. Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)

    Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) with bevacizumab (Avastin) for treating metastatic colorectal cancer after 2 systemic treatments in adults.